Wentao Sun
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Wentao Sun has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
- Bohao Zheng
Department of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China
1 shared publication - Brian M. Yan
The Chinese University of Hong Kong , Hong Kong , Hong Kong
1 shared publication - Changhai Liu
State Key Laboratory for Crop Stress Resistance and High‐Efficiency Production/Shaanxi Key Laboratory of Apple, College of Horticulture Northwest A&F University Yangling Shaanxi China
1 shared publication Cuie Wei
Department of Plastic Surgery, The First People’s Hospital of Lianyungang, Lianyungang, China
1 shared publicationDehua Wang
College of Physics, Qingdao University, Qingdao, CHINA
1 shared publicationFanjun Meng
Department of Plastic Surgery, The First People’s Hospital of Lianyungang, Lianyungang, China
1 shared publication
Latest Publications
- Open Access
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Impact of sodium-glucose co-transporter 2 inhibitors on cardiovascular outcomes in patients with chronic kidney disease: Hong Kong-wide, observational, propensity score matched analysis
Purpose: The impact of SGLT2i on patients with advanced chronic kidney disease (CKD) is limited. We aimed to compare hospitalization for heart failure (HHF) and cardiovascular (CV) death between new users of SGLT2i versus non-users across the spectrum of CKD stages. Methods: We retrospectively analyzed 22,657 patients with CKD who were prescribed SGLT2i between August 2015 and August 2020 in 16 public hospitals in Hong Kong. Propensity-matched cohorts of SGLT2i users and non-users (n=3,704 per group) were generated on the basis of age, gender, baseline eGFR, co-morbidities and medications. Time to HHF and CV death was analyzed using COX proportional hazards model. Subgroup analysis was performed to detect heterogeneity of effect across stages of CKD. Results: Of the whole cohort (N=22,657), the percentage of SGLT2i users in CKD stage G1 to G5 were 82.1%, 49.0%, 19.8%, 10.3%, 4.3%, and 1.6%, respectively. SGLT2i users and non-users groups were well balanced at baseline (mean age 64.7±12.7, female 37.1%), with a median follow-up of 2.8 (IQR: 1.1–5.1) years (22876.5 person-years). Overall, SGLT2i was associated with reduced risk of HHF (Hazards Ratio (HR) 0.12 (95% CI (0.10–0.16) and CV death (HR 0.17 (95% CI (0.12–0.25), compared with non-users. Subgroup analysis demonstrated benefit of SGLT2i on CV death in G3 to G5 groups but not in patients in earlier CKD stages (P for interaction <0.001) (Table). Reduction in risk of HHF was comparable across all CKD stages (P for interaction = 0.1). Conclusion: Utilization of SGLT2i was associated with significant reduction in HHF and CV death in patients with moderate to severe CKD in a real-world setting. Our results suggest significant heterogeneity in CV death reduction with the largest benefit in patients with stage G3a and more advanced CKD. Funding Acknowledgement: Type of funding sources: None.
- 1 October 2022
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 43 (Supplement)
Open AccessImpact of sodium-glucose co-transporter 2 inhibitors on cardiovascular outcomes in patients with chronic kidney disease: Hong Kong-wide, observational, propensity score matched analysis
Purpose: The impact of SGLT2i on patients with advanced chronic kidney disease (CKD) is limited. We aimed to compare hospitalization for heart failure (HHF) and cardiovascular (CV) death between new users of SGLT2i versus non-users across the spectrum of CKD stages. Methods: We retrospectively analyzed 22,657 patients with CKD who were prescribed SGLT2i between August 2015 and August 2020 in 16 public hospitals in Hong Kong. Propensity-matched cohorts of SGLT2i users and non-users (n=3,704 per group) were generated on the basis of age, gender, baseline eGFR, co-morbidities and medications. Time to HHF and CV death was analyzed using COX proportional hazards model. Subgroup analysis was performed to detect heterogeneity of effect across stages of CKD. Results: Of the whole cohort (N=22,657), the percentage of SGLT2i users in CKD stage G1 to G5 were 82.1%, 49.0%, 19.8%, 10.3%, 4.3%, and 1.6%, respectively. SGLT2i users and non-users groups were well balanced at baseline (mean age 64.7±12.7, female 37.1%), with a median follow-up of 2.8 (IQR: 1.1–5.1) years (22876.5 person-years). Overall, SGLT2i was associated with reduced risk of HHF (Hazards Ratio (HR) 0.12 (95% CI (0.10–0.16) and CV death (HR 0.17 (95% CI (0.12–0.25), compared with non-users. Subgroup analysis demonstrated benefit of SGLT2i on CV death in G3 to G5 groups but not in patients in earlier CKD stages (P for interaction <0.001) (Table). Reduction in risk of HHF was comparable across all CKD stages (P for interaction = 0.1). Conclusion: Utilization of SGLT2i was associated with significant reduction in HHF and CV death in patients with moderate to severe CKD in a real-world setting. Our results suggest significant heterogeneity in CV death reduction with the largest benefit in patients with stage G3a and more advanced CKD. Funding Acknowledgement: Type of funding sources: None.
- Open Access
- 9 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-12
Liquid-liquid triboelectric nanogenerator based on the immiscible interface of an aqueous two-phase system
Solid nanogenerators often have limited charge transfer due to their low contact area. Liquid–liquid nanogenerators can transfer a charge better than the solid–solid and solid–liquid counterparts. However, the precise manipulation of the liquid morphology remains a challenge because of the fluidity limits of the liquid. In this work, using the surface tension of a droplet to fix its shape, a liquid-liquid triboelectric nanogenerator in Contact-Separation mode is designed using an immiscible aqueous-aqueous interface, achieving a contact surface charge transfer of 129 nC for a single droplet. The configuration is proven to be applicable in humid environments, and the two-phase materials have good biocompatibility and can be used as an effective drug carrier. Therefore, this nanogenerator is useful for designing future implantable devices. Meanwhile, this design also establishes the foundation of aqueous electronics, and additional applications can be achieved using this route.
- 9 September 2022
- Published by Springer Nature in Nature Communications
- Vol. 13 (1) , 1-12
Open AccessLiquid-liquid triboelectric nanogenerator based on the immiscible interface of an aqueous two-phase system
Solid nanogenerators often have limited charge transfer due to their low contact area. Liquid–liquid nanogenerators can transfer a charge better than the solid–solid and solid–liquid counterparts. However, the precise manipulation of the liquid morphology remains a challenge because of the fluidity limits of the liquid. In this work, using the surface tension of a droplet to fix its shape, a liquid-liquid triboelectric nanogenerator in Contact-Separation mode is designed using an immiscible aqueous-aqueous interface, achieving a contact surface charge transfer of 129 nC for a single droplet. The configuration is proven to be applicable in humid environments, and the two-phase materials have good biocompatibility and can be used as an effective drug carrier. Therefore, this nanogenerator is useful for designing future implantable devices. Meanwhile, this design also establishes the foundation of aqueous electronics, and additional applications can be achieved using this route.
- Open Access
- 10 May 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 897440
Hsa_circ_0062270 Promotes Tumorigenesis of Melanoma by Stabilizing the Linear Transcript Cell Division Cycle Protein 45
Background: To elucidate the potential biological function of hsa_circ_0062270 in the malignant process of melanoma and its potential target.Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to examine relative level of hsa_circ_0062270 in melanoma tissues and normal skin tissues. The diagnostic and prognostic potentials of hsa_circ_0062270 in melanoma were evaluated. The regulatory effect of hsa_circ_0062270 on the expression of linear transcript Cell division cycle protein 45 (CDC45) was also examined.Results: Hsa_circ_0062270 was up-regulated in melanoma samples and cell lines, which displayed certain diagnostic and prognostic potentials in melanoma. Inhibition of hsa_circ_0062270 attenuated the proliferative, migratory and invasive functions. Hsa_circ_0062270 could stabilize the expression of linear transcript CDC45, and thus participated in the malignant process of melanoma.Conclusion: Hsa_circ_0062270 promotes proliferative, migratory and invasive functions of melanoma cells via stabilizing the linear transcript CDC45. Hsa_circ_0062270 can be used to diagnosis and treatment of melanoma.
- 10 May 2022
- Published by Frontiers Media SA in Frontiers in Genetics
- Vol. 13, 897440
Open AccessHsa_circ_0062270 Promotes Tumorigenesis of Melanoma by Stabilizing the Linear Transcript Cell Division Cycle Protein 45
Background: To elucidate the potential biological function of hsa_circ_0062270 in the malignant process of melanoma and its potential target.Methods: Quantitative real-time polymerase chain reaction (qRT-PCR) was conducted to examine relative level of hsa_circ_0062270 in melanoma tissues and normal skin tissues. The diagnostic and prognostic potentials of hsa_circ_0062270 in melanoma were evaluated. The regulatory effect of hsa_circ_0062270 on the expression of linear transcript Cell division cycle protein 45 (CDC45) was also examined.Results: Hsa_circ_0062270 was up-regulated in melanoma samples and cell lines, which displayed certain diagnostic and prognostic potentials in melanoma. Inhibition of hsa_circ_0062270 attenuated the proliferative, migratory and invasive functions. Hsa_circ_0062270 could stabilize the expression of linear transcript CDC45, and thus participated in the malignant process of melanoma.Conclusion: Hsa_circ_0062270 promotes proliferative, migratory and invasive functions of melanoma cells via stabilizing the linear transcript CDC45. Hsa_circ_0062270 can be used to diagnosis and treatment of melanoma.
- 26 January 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (6) , 1368-1378
del Nido cardioplegia better preserves cardiac diastolic function but histidine–tryptophan–ketoglutarate is better for endothelial function
The effectiveness of myocardial protection of cardioplegia has been a matter of debate for decades. This study was designed to compare cardiac and endothelial protection of 3 clinically used cardioplegias: del Nido cardioplegia (DNC), histidine–tryptophan–ketoglutarate (HTK) and blood cardioplegia (BC) followed by HTK (BC + HTK) in a rat model of ischaemia/reperfusion (I/R). Sixty male Wistar rats were subjected to either 120 min of global ischaemia at 4°C followed by 90 min of reperfusion (I/R) at 37°C or no I/R (control) in a Langendorff apparatus and were randomly allocated to 5 groups: control, I/R, DNC, HTK and BC + HTK. Cold cardioplegia solutions were administered at doses of 20 ml/kg for DNC and HTK or 10 ml/kg for BC followed by HTK. Haemodynamic parameters were continuously recorded using an intraventricular balloon. The endothelium-dependent relaxation to acetylcholine was measured in the left anterior descending artery using a myograph. Protein expression of cardiac troponin T (cTnT) and creatine kinase MB was determined by western blot. During reperfusion, HTK had higher left ventricular systolic pressure whereas DNC had lower left ventricular end-diastolic pressure, better left ventricular developed pressure and best +dp/dtmax and −dp/dtmax than the other 2 groups but the differences disappeared at the end of the reperfusion. HTK or BC + HTK preserves the acetylcholine-induced endothelium-dependent relaxation better than DNC (Emax = 48.2 ± 8.0% in DNC vs 75.0 ± 8.0% in HTK, P < 0.05; vs 96.9 ± 3.5% in BC + HTK, P < 0.001). The protein levels of cTnT and creatine kinase MB were downregulated in the 3 groups. All 3 cardioplegias prevented myocardial damage against I/R injury at the end of reperfusion. DNC demonstrated better preserved diastolic function of the left ventricle whereas HTK or BC + HTK showed better preserved coronary endothelial function. These findings may suggest that currently no ‘perfect’ cardioplegia exists and that exploration for the ‘perfect’ cardioplegia is needed.
- 26 January 2022
- Published by Oxford University Press (OUP) in European Journal of Cardio-Thoracic Surgery
- Vol. 61 (6) , 1368-1378
del Nido cardioplegia better preserves cardiac diastolic function but histidine–tryptophan–ketoglutarate is better for endothelial function
The effectiveness of myocardial protection of cardioplegia has been a matter of debate for decades. This study was designed to compare cardiac and endothelial protection of 3 clinically used cardioplegias: del Nido cardioplegia (DNC), histidine–tryptophan–ketoglutarate (HTK) and blood cardioplegia (BC) followed by HTK (BC + HTK) in a rat model of ischaemia/reperfusion (I/R). Sixty male Wistar rats were subjected to either 120 min of global ischaemia at 4°C followed by 90 min of reperfusion (I/R) at 37°C or no I/R (control) in a Langendorff apparatus and were randomly allocated to 5 groups: control, I/R, DNC, HTK and BC + HTK. Cold cardioplegia solutions were administered at doses of 20 ml/kg for DNC and HTK or 10 ml/kg for BC followed by HTK. Haemodynamic parameters were continuously recorded using an intraventricular balloon. The endothelium-dependent relaxation to acetylcholine was measured in the left anterior descending artery using a myograph. Protein expression of cardiac troponin T (cTnT) and creatine kinase MB was determined by western blot. During reperfusion, HTK had higher left ventricular systolic pressure whereas DNC had lower left ventricular end-diastolic pressure, better left ventricular developed pressure and best +dp/dtmax and −dp/dtmax than the other 2 groups but the differences disappeared at the end of the reperfusion. HTK or BC + HTK preserves the acetylcholine-induced endothelium-dependent relaxation better than DNC (Emax = 48.2 ± 8.0% in DNC vs 75.0 ± 8.0% in HTK, P < 0.05; vs 96.9 ± 3.5% in BC + HTK, P < 0.001). The protein levels of cTnT and creatine kinase MB were downregulated in the 3 groups. All 3 cardioplegias prevented myocardial damage against I/R injury at the end of reperfusion. DNC demonstrated better preserved diastolic function of the left ventricle whereas HTK or BC + HTK showed better preserved coronary endothelial function. These findings may suggest that currently no ‘perfect’ cardioplegia exists and that exploration for the ‘perfect’ cardioplegia is needed.
- 2 July 2021
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 44 (7-8) , 390-399
Adjuvant Therapy in Resected Nonmetastatic Stage II–IV Gallbladder Cancer: A Generalized Propensity Score Analysis
Background: The clinical benefits and efficacies of adjuvant therapies for gallbladder cancer (GBC) have not been verified due to insufficient clinical evidence. Methods: Patients with resected nonmetastatic stage II–IV GBC were selected from the Surveillance, Epidemiology, and End Results database and distributed into nonchemotherapy and chemoradiotherapy (NCRT), chemotherapy (CT), and chemoradiotherapy (CRT) groups. Generalized propensity score and inverse probability of treatment weighting (IPTW) were used to reduce the imbalances between groups. Results: A total of 2,689 patients were enrolled, among whom 1,193 (44.4%) were classified as stage II, 1,371 (51.0%) as stage III, and 125 (4.6%) as stage IV GBC. A total of 1,703, 444, and 542 patients were placed in the NCRT, CT, and CRT groups, respectively. After the IPTW, there were no significant differences in overall survival (OS) between the 3 treatment groups (p > 0.05) in stage II GBC patients. In patients with stage III–IV GBC, the CT group exhibited a superior OS compared to the NCRT group (p < 0.001). In addition, the CRT group exhibited a superior OS compared to the CT (p < 0.001) and NCRT (p < 0.001) groups. For patients with stage III–IV tumors, a nomogram was constructed to predict the survival benefits of adjuvant therapies. Conclusion: Patients with stage II GBC may not benefit from adjuvant therapy, while patients with stage III–IV GBC were shown to benefit from chemotherapy and chemoradiotherapy. Furthermore, chemoradiotherapy exhibited a superior OS. Nevertheless, the results need to be explained in the context of retrospective studies.
- 2 July 2021
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 44 (7-8) , 390-399
Adjuvant Therapy in Resected Nonmetastatic Stage II–IV Gallbladder Cancer: A Generalized Propensity Score Analysis
Background: The clinical benefits and efficacies of adjuvant therapies for gallbladder cancer (GBC) have not been verified due to insufficient clinical evidence. Methods: Patients with resected nonmetastatic stage II–IV GBC were selected from the Surveillance, Epidemiology, and End Results database and distributed into nonchemotherapy and chemoradiotherapy (NCRT), chemotherapy (CT), and chemoradiotherapy (CRT) groups. Generalized propensity score and inverse probability of treatment weighting (IPTW) were used to reduce the imbalances between groups. Results: A total of 2,689 patients were enrolled, among whom 1,193 (44.4%) were classified as stage II, 1,371 (51.0%) as stage III, and 125 (4.6%) as stage IV GBC. A total of 1,703, 444, and 542 patients were placed in the NCRT, CT, and CRT groups, respectively. After the IPTW, there were no significant differences in overall survival (OS) between the 3 treatment groups (p > 0.05) in stage II GBC patients. In patients with stage III–IV GBC, the CT group exhibited a superior OS compared to the NCRT group (p < 0.001). In addition, the CRT group exhibited a superior OS compared to the CT (p < 0.001) and NCRT (p < 0.001) groups. For patients with stage III–IV tumors, a nomogram was constructed to predict the survival benefits of adjuvant therapies. Conclusion: Patients with stage II GBC may not benefit from adjuvant therapy, while patients with stage III–IV GBC were shown to benefit from chemotherapy and chemoradiotherapy. Furthermore, chemoradiotherapy exhibited a superior OS. Nevertheless, the results need to be explained in the context of retrospective studies.
- Open Access
- 9 April 2021
- Published by Frontiers Media SA in Pathology and Oncology Research
- Vol. 27, 632531
UBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma
Background: The ubiquitin-conjugating enzyme E2 T (UBE2T) has been shown to contribute to several types of cancer. However, no publication has reported its implication in esophageal squamous cell cancer (ESCC).Methods: We explored several public databases, including The Cancer Genome Atlas (TCGA), Oncomine, and gene expression Omnibus (GEO). Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and gene set enrichment analysis (GSEA) were adopted to explore involved signaling pathways. We used R software to develop prognostic gene signatures with the LASSO and stepwise Cox regression analysis, separately. Immunohistochemistry staining was performed to detect UBE2T in 90 ESCC patients, followed by survival analysis. We also used an R package pRRophetic to evaluate chemotherapy sensitivity for the TCGA–ESCC cohort.Results: We found significantly increased UBE2T transcript levels and DNA copy numbers in ESCC tissues. UBE2T was associated with the p53 signaling pathway, cell cycle, Fanconi anemia pathway, and DNA replication, as indicated by Go, KEGG pathway enrichment analysis. These pathways were also upregulated in ESCC. The prognostic signatures with UBE2T-associated genes could stratify ESCC patients into low- and high-risk groups with significantly different overall survival in the TCGA–ESCC cohort. We also validated the association of UBE2T with unfavorable survival in 90 ESCC patients recruited for this study. Moreover, we found that the low-risk group was significantly more sensitive to chemotherapy than the high-risk group.Conclusions: UBE2T is involved in the development of ESCC, and gene signatures derived from UBE2T-associated genes are predictive of prognosis in ESCC.
- 9 April 2021
- Published by Frontiers Media SA in Pathology and Oncology Research
- Vol. 27, 632531
Open AccessUBE2T Contributes to the Prognosis of Esophageal Squamous Cell Carcinoma
Background: The ubiquitin-conjugating enzyme E2 T (UBE2T) has been shown to contribute to several types of cancer. However, no publication has reported its implication in esophageal squamous cell cancer (ESCC).Methods: We explored several public databases, including The Cancer Genome Atlas (TCGA), Oncomine, and gene expression Omnibus (GEO). Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis, and gene set enrichment analysis (GSEA) were adopted to explore involved signaling pathways. We used R software to develop prognostic gene signatures with the LASSO and stepwise Cox regression analysis, separately. Immunohistochemistry staining was performed to detect UBE2T in 90 ESCC patients, followed by survival analysis. We also used an R package pRRophetic to evaluate chemotherapy sensitivity for the TCGA–ESCC cohort.Results: We found significantly increased UBE2T transcript levels and DNA copy numbers in ESCC tissues. UBE2T was associated with the p53 signaling pathway, cell cycle, Fanconi anemia pathway, and DNA replication, as indicated by Go, KEGG pathway enrichment analysis. These pathways were also upregulated in ESCC. The prognostic signatures with UBE2T-associated genes could stratify ESCC patients into low- and high-risk groups with significantly different overall survival in the TCGA–ESCC cohort. We also validated the association of UBE2T with unfavorable survival in 90 ESCC patients recruited for this study. Moreover, we found that the low-risk group was significantly more sensitive to chemotherapy than the high-risk group.Conclusions: UBE2T is involved in the development of ESCC, and gene signatures derived from UBE2T-associated genes are predictive of prognosis in ESCC.
- Open Access
- 8 August 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (11) , 1501-1509
Treatment patterns of prostate cancer with bone metastasis in Beijing: A real‐world study using data from an administrative claims database
Purpose: To explore treatment patterns among patients with prostate cancer and bone metastasis and to compare clinical outcomes following use of different hormone therapies including combined androgen blockade (CAB), nonsteroidal antiandrogen (NSAA) monotherapy, and castration monotherapy.Methods: We conducted a population‐based cohort study using data from the Urban Employee Basic Medical Insurance database (2011‐2014) in Beijing. We identified 475 patients with newly diagnosed bone metastatic prostate cancer with at least one prescription for hormone therapy and described their treatment patterns over a median follow‐up of 20.7 months. Cox proportional hazards model was used to compare time to chemotherapy initiation between patients starting on different hormone therapies.Results: Hormone therapy and/or bisphosphonate therapy with zoledronic acid were the initial treatments in the majority of patients (87.8%); chemotherapy, radiotherapy, and surgery were usually given later in the treatment pathway. CAB was the most common hormone treatment (73.7%). For time to chemotherapy initiation, hazard ratios (95% confidence intervals) were 2.43 (1.08‐5.44) for NSAA alone vs CAB and 1.29 (0.78‐2.13) for castration alone vs CAB.Conclusions: Our findings show that while a wide range of therapies are used to treat patients with prostate cancer and bone metastasis in Beijing, hormone therapy and bisphosphonate therapy are the most commonly prescribed, and use of CAB was seen to be advantageous in delaying time to chemotherapy initiation over NSAA monotherapy. Future studies should explore longer‐term treatment patterns, including use of newly approved treatments.
- 8 August 2019
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 28 (11) , 1501-1509
Open AccessTreatment patterns of prostate cancer with bone metastasis in Beijing: A real‐world study using data from an administrative claims database
Purpose: To explore treatment patterns among patients with prostate cancer and bone metastasis and to compare clinical outcomes following use of different hormone therapies including combined androgen blockade (CAB), nonsteroidal antiandrogen (NSAA) monotherapy, and castration monotherapy.Methods: We conducted a population‐based cohort study using data from the Urban Employee Basic Medical Insurance database (2011‐2014) in Beijing. We identified 475 patients with newly diagnosed bone metastatic prostate cancer with at least one prescription for hormone therapy and described their treatment patterns over a median follow‐up of 20.7 months. Cox proportional hazards model was used to compare time to chemotherapy initiation between patients starting on different hormone therapies.Results: Hormone therapy and/or bisphosphonate therapy with zoledronic acid were the initial treatments in the majority of patients (87.8%); chemotherapy, radiotherapy, and surgery were usually given later in the treatment pathway. CAB was the most common hormone treatment (73.7%). For time to chemotherapy initiation, hazard ratios (95% confidence intervals) were 2.43 (1.08‐5.44) for NSAA alone vs CAB and 1.29 (0.78‐2.13) for castration alone vs CAB.Conclusions: Our findings show that while a wide range of therapies are used to treat patients with prostate cancer and bone metastasis in Beijing, hormone therapy and bisphosphonate therapy are the most commonly prescribed, and use of CAB was seen to be advantageous in delaying time to chemotherapy initiation over NSAA monotherapy. Future studies should explore longer‐term treatment patterns, including use of newly approved treatments.
- 6 July 2015
- Published by AIP Publishing in Applied Physics Letters
- Vol. 107 (1) , 013901
Transparent conducting oxide free backside illuminated perovskite solar cells
Recently, hybrid perovskites have attracted great attention because of their promising applications in solar cells. However, perovskite solar devices reported till now are mostly based on transparent conducting oxide (TCO) substrates which account for a large proportion in the total cost. Herein, TCO-free perovskite solar cells are fabricated. A photo-electricity conversion efficiency of 5.27% is obtained with short circuit current density (Jsc) of 10.7 mA/cm2, open circuit voltage (Voc) of 0.837 V, and fill factor of 0.588. This study points a feasible way of replacing TCO substrate by low cost substrates, indicating promising potentials in solar energy conversion applications.
- 6 July 2015
- Published by AIP Publishing in Applied Physics Letters
- Vol. 107 (1) , 013901
Transparent conducting oxide free backside illuminated perovskite solar cells
Recently, hybrid perovskites have attracted great attention because of their promising applications in solar cells. However, perovskite solar devices reported till now are mostly based on transparent conducting oxide (TCO) substrates which account for a large proportion in the total cost. Herein, TCO-free perovskite solar cells are fabricated. A photo-electricity conversion efficiency of 5.27% is obtained with short circuit current density (Jsc) of 10.7 mA/cm2, open circuit voltage (Voc) of 0.837 V, and fill factor of 0.588. This study points a feasible way of replacing TCO substrate by low cost substrates, indicating promising potentials in solar energy conversion applications.
- Open Access
- 1 January 2015
- Published by AIP Publishing in AIP Advances
- Vol. 5 (1) , 017141
TiO2 hierarchical nanostructures: Hydrothermal fabrication and application in dye-sensitized solar cells
Arrays of TiO2 hierarchical nanostructures that consisted of rutile nanorods and anatase branches were hydrothermally fabricated and employed as photoanodes in dye-sensitized solar cells (DSSCs). Each hierarchical nanostructure array was attained in two steps. First, a primary nanorod array was synthesized in aqueous solutions of hydrochloric acid (HCl) and tetrabutyl titanate (C16H36O4Ti); subsequently, secondary branches were grown on the nanorods in aqueous solutions of ammonium hexafluorotitanate ((NH4)2TiF6) and boric acid (H3BO3). The secondary anatase branches filled part of the space among the primary rutile nanorods and gave rise to a larger surface area. Light-harvesting capability of the DSSCs with TiO2 hierarchical nanostructures as photoanodes was appreciably improved because more dye molecules could be loaded on the photoanodes and more light could be scattered inside the DSSCs. Therefore, the conversion efficiencies of the DSSCs were doubled by replacing the photoanode of primary TiO2 nanorod array with the photoanodes of TiO2 hierarchical nanostructure arrays. Furthermore, in order to reach a compromise between the photoanode surface area and the inter-nanorod space volume, the growth time of the secondary TiO2 anatase branches was optimized.
- 1 January 2015
- Published by AIP Publishing in AIP Advances
- Vol. 5 (1) , 017141
Open AccessTiO2 hierarchical nanostructures: Hydrothermal fabrication and application in dye-sensitized solar cells
Arrays of TiO2 hierarchical nanostructures that consisted of rutile nanorods and anatase branches were hydrothermally fabricated and employed as photoanodes in dye-sensitized solar cells (DSSCs). Each hierarchical nanostructure array was attained in two steps. First, a primary nanorod array was synthesized in aqueous solutions of hydrochloric acid (HCl) and tetrabutyl titanate (C16H36O4Ti); subsequently, secondary branches were grown on the nanorods in aqueous solutions of ammonium hexafluorotitanate ((NH4)2TiF6) and boric acid (H3BO3). The secondary anatase branches filled part of the space among the primary rutile nanorods and gave rise to a larger surface area. Light-harvesting capability of the DSSCs with TiO2 hierarchical nanostructures as photoanodes was appreciably improved because more dye molecules could be loaded on the photoanodes and more light could be scattered inside the DSSCs. Therefore, the conversion efficiencies of the DSSCs were doubled by replacing the photoanode of primary TiO2 nanorod array with the photoanodes of TiO2 hierarchical nanostructure arrays. Furthermore, in order to reach a compromise between the photoanode surface area and the inter-nanorod space volume, the growth time of the secondary TiO2 anatase branches was optimized.